Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The immunoglobulin heavy chain variable region third complementarity-determining region (CDR-H3, HCDR3) is a highly diverse polypeptide segment within the variable domain of the heavy chain of antibodies. It is formed by V(D)J recombination, incorporating sequence from variable (V), diversity (D), and joining (J) gene segments, with additional junctional diversity generated during B cell development[2][3][1]. CDR-H3 constitutes the central part of the antibody's antigen-binding site, and it is the most diverse region among all six antibody CDRs. This diversity underlies the enormous antigen recognition potential of the adaptive immune system, making CDR-H3 critical for the specificity and affinity of antibody-antigen binding[3][7][1]. In biomedical research and diagnostics, the sequence and length of heavy chain CDR3 regions serve as molecular fingerprints for B cell clonality and immune repertoire profiling, such as in lymphoma diagnostics or neutralizing antibody studies[4][6]. Summary: This entry refers to a functionally critical region of antibodies, not a discrete molecular target such as a receptor or enzyme, and should not be considered a canonical therapeutic target. The proper context for CDR-H3 is as a sequence feature within immunoglobulins, essential for antigen recognition, immune diversity, and as a molecular biomarker in immune profiling, but not itself an actionable therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin heavy chain variable region third complementarity-determining region (CDR-H3).